Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A4 | P14672 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gapicomine SCHEMBL1037773 | 0.86 | SLC2A4 (0.61) | SLC2A4GAAALDH1A1CYP2D6CYP1A2 | |
| SCHEMBL10054983 | 0.84 | SLC2A4 (0.59) | SLC2A4GAAALDH1A1CYP2D6CYP1A2 | |
| Gapicomine SCHEMBL9336954 | 0.84 | SLC2A4 (0.59) | SLC2A4GAAALDH1A1CYP2D6CYP1A2 | |
| Gapicomine SCHEMBL6121683 | 0.84 | SLC2A4 (0.59) | SLC2A4GAAALDH1A1CYP2D6CYP1A2 | |
| SCHEMBL61635 | 0.79 | CYP17A1 (0.48) | ALDH1A1CYP2D6CYP1A2CYP3A4LOXL2 | |
| SCHEMBL22305387 | 0.79 | SLC2A4 (0.60) | SLC2A4GAAALDH1A1CYP2D6CYP1A2 | |
| SCHEMBL28330956 | 0.79 | F2 (0.49) | GAAALDH1A1KDM4E | |
| SCHEMBL1043672 | 0.79 | SLC2A4 (0.51) | SLC2A4GAAALDH1A1CYP2D6CYP1A2 | |
| SCHEMBL1044020 | 0.79 | CYP1A2 (0.75) | ALDH1A1CYP2D6CYP1A2 | |
| SCHEMBL2983745 | 0.77 | DRD4 (0.54) | ALDH1A1KDM4EGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1725528-B1 | SULPHONYLPYRROLES AS HDAC INHIBITORS | 4SC AG (DE) | 2013-05-29 | — | — | EP | claimed |
| WO-2019043176-A2 | HDAC INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY | 4SC AG (DE) | 2019-03-07 | — | — | WO | disclosed |
| US-8969401-B2 | Sulfonylpyrroles | 4SC AG (DE) | 2015-03-03 | — | — | US | disclosed |
| EP-1725528-B1 | SULPHONYLPYRROLES AS HDAC INHIBITORS | 4SC AG (DE) | 2013-05-29 | — | — | EP | disclosed |
| US-20130079347-A1 | NOVEL SULFONYLPYRROLES | ALTANA PHARMA AG (DE) | 2013-03-28 | — | — | US | disclosed |
| US-8399505-B2 | Sulfonylpyrroles | 4SC AG (DE) | 2013-03-19 | — | — | US | disclosed |
| US-8232297-B2 | Sulphonylpyrroles as inhibitors of HDACs novel sulphonylpyrroles | 4SC AG (DE) | 2012-07-31 | — | — | US | disclosed |
| US-8188138-B2 | Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors | 4SC AG (DE) | 2012-05-29 | — | — | US | disclosed |
| US-8067615-B2 | Sulphonylpyrroles | 4SC AG (DE) | 2011-11-29 | — | — | US | disclosed |
| US-20110166140-A1 | NOVEL SULPHONYLPYRROLES | MAIER THOMAS | 2011-07-07 | — | — | US | disclosed |
| US-20100261721-A1 | Novel Sulphonylpyrroles | MAIER THOMAS | 2010-10-14 | — | — | US | disclosed |
| US-20090297473-A1 | Sulphonylpyrrole Hydrochloride Salts as Histone Deacetylases Inhibitors | NYCOMED GMBH (DE) | 2009-12-03 | — | — | US | disclosed |
| US-20090263353-A1 | Novel Sulphonylpyrroles as Inhibitors of Hdac S Novel Sulphonylpyrroles | NYCOMED GMBH (DE) | 2009-10-22 | — | — | US | disclosed |
| EP-1928872-A1 | NOVEL SULPHONYLPYRROLES AS INHIBITORS OF HDAC S NOVEL SULPHONYLPYRROLES | Nycomed GmbH (DE) | 2008-06-11 | — | — | EP | disclosed |
| EP-1928826-A1 | SULPHONYLPYRROLE HYDROCHLORIDE SALTS AS HISTONE DEACETYLASES INHIBITORS | Nycomed GmbH (DE) | 2008-06-11 | — | — | EP | disclosed |
| US-20070184979-A1 | Novel sulfonylpyrroles | ALTANA PHARMA AG (DE) | 2007-08-09 | — | — | US | disclosed |
| WO-2007039404-A1 | NOVEL SULPHONYLPYRROLES AS INHIBITORS OF HDAC S NOVEL SULPHONYLPYRROLES | NYCOMED GMBH (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039403-A1 | SULPHONYLPYRROLE HYDROCHLORIDE SALTS AS HISTONE DEACETYLASES INHIBITORS | NYCOMED GMBH (DE) | 2007-04-12 | — | — | WO | disclosed |
| EP-1725528-A2 | SULPHONYLPYRROLES AS HDAC INHIBITORS | Altana Pharma AG (DE) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005087724-A2 | SULPHONYLPYRROLES AS HDAC INHIBITORS | ALTANA PHARMA AG (DE) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090263353-A1 | Novel Sulphonylpyrroles as Inhibitors of Hdac S Novel Sulphonylpyrroles | HDAC1, HDAC3, HDAC2 | SLC2A4 3862/4885GAA 2212/4885ALDH1A1 1174/4885 |
| US-20070184979-A1 | Novel sulfonylpyrroles | HDAC1, HDAC4, HDAC3 | SLC2A4 924/4885GAA 672/4885ALDH1A1 389/4885 |
| US-20110166140-A1 | NOVEL SULPHONYLPYRROLES | HDAC1, HDAC3, HDAC2 | SLC2A4 4078/4885GAA 3008/4885ALDH1A1 897/4885 |
| US-20100261721-A1 | Novel Sulphonylpyrroles | HDAC1, HDAC3, HDAC2 | SLC2A4 4078/4885GAA 3008/4885ALDH1A1 897/4885 |
| US-20090297473-A1 | Sulphonylpyrrole Hydrochloride Salts as Histone Deacetylases Inhibitors | HDAC1, HDAC3, HDAC2 | SLC2A4 3414/4885GAA 2067/4885ALDH1A1 744/4885 |
| US-20130079347-A1 | NOVEL SULFONYLPYRROLES | HDAC3, HDAC1, HDAC2 | SLC2A4 1748/4885GAA 1988/4885ALDH1A1 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.